TATAA Biocenter Becomes Certified Qualified Service Provider for HTG Molecular Diagnostics

TATAA Biocenter, a leading provider of high-quality molecular analysis services, has announced its certification as a Qualified Service Provider for HTG Molecular Diagnostics. TATAA will be able to offer high-throughput, multiplex gene expression profiling to its customers as well as expand its portfolio of molecular analysis services as a result of this certification. HTG Molecular Diagnostics is a life science company that uses HTG EdgeSeq, an innovative transcriptome-wide profiling technology, to advance precision medicine. Researchers can study a large number of genes at the same time using this highly sensitive and specific method of analysing gene expression.

This technology is especially useful for oncology, immunology, and neurology research that requires the analysis of complex gene expression profiles. Unlike RNA-Seq, HTG EdgeSeq technology does not require RNA extraction and can generate reproducible gene expression profiles from small amounts of tissue material (typically several mm2). "We are thrilled to be a certified qualified service provider for HTG technology," said Mikael Kubista, founder and CEO of TATAA Biocenter. "Our team of scientists has received extensive training in this technology, and we are well-equipped to provide the highest-quality service for high-throughput, multiplex gene expression profiling to our customers."

"Your commitment to excellence and dedication to providing world-class service has been truly inspiring, and we are thrilled to have you as a partner," said Selina Gaertner, director of EU Medical Affairs at HTG Molecular Diagnostics. "We are delighted to have TATAA Biocenter among our select group of Qualified Service Providers." They are the ideal service to recommend to our end users, running our technology with high standards and professionalism," said Jean Claude Gerard, vice president of global sales at HTG Molecular Diagnostics. "This certification demonstrates our commitment to providing the most advanced genomic services available to our customers."

We can now provide even more comprehensive solutions for gene expression profiling and biomarker discovery thanks to HTG EdgeSeq technology." Jens Björkman, COO of TATAA Biocenter, also commented. TATAA Biocenter is a forerunner in the provision of qPCR, digital PCR, and Next-Generation Sequencing (NGS) services and products to customers in academia, industry, and healthcare. TATAA Biocenter continues to expand its portfolio of advanced molecular biology technologies with this certification, providing its clients with the most innovative and dependable solutions for their research and clinical needs.

TATAA Biocenter is a leading provider of molecular services to Europe's Advanced Therapies and Medical Products (ATMP) industry and the United States' Cell and Gene Therapy industry. HTG is advancing precision medicine from diagnosis to treatment by leveraging the power of transcriptome-wide profiling to drive translational research, clinical diagnostics, and targeted therapeutics in a wide range of disease areas.